N.J. Admin. Code § 13:39-13.3

Current through Register Vol. 56, No. 24, December 18, 2024

Section 13:39-13.3 - Board approval; pharmacist qualifications; continuing education

(a) In order to enter into an agreement to engage in the collaborative drug therapy management of a patient with a physician licensed in this State, a licensed pharmacist shall be pre-approved by the Board to engage in such activity. In order to obtain Board approval, a pharmacist shall submit a collaborative practice application and documentation that establishes that he or she has successfully completed one of the following:

1. A certificate training program offered by an Accreditation Council for Pharmacy Education (ACPE)-approved provider;

2. A post-graduate residency program accredited by the American Society of Health-System Pharmacists; or

3. A certification program from the Board of Pharmacy Specialties.

(b) The Board shall issue an authorization to engage in collaborative drug therapy management to a pharmacist who, upon application to the Board, demonstrates satisfaction of the requirements of (a) above.

(c) A pharmacist granted authorization to engage in collaborative drug therapy management pursuant to this section shall complete a minimum of 10 credits of continuing education every biennial renewal period in each disease(s) or condition(s) covered by the collaborative practice agreement(s) to which he or she is a party, consistent with the requirements of N.J.A.C. 13:39-3A. However, to the extent that a pharmacist may enter into collaborative practice agreements to treat patients with co-existing, interrelated conditions or diseases, a pharmacist need only complete a total of 10 credits in the interrelated conditions or diseases.

N.J. Admin. Code § 13:39-13.3

Administrative Change, 54 N.J.R. 1977(a), effective 9/21/2022